CosmosID nets $6M for in silico, pan-microbial diagnostic
CosmosID's powerful diagnostic platform can identify some 20,000 microbes, based on an intricate understanding of microbial biomarkers.
CosmosID's powerful diagnostic platform can identify some 20,000 microbes, based on an intricate understanding of microbial biomarkers.
Researchers at Columbia University have developed an algorithm that can determine how an individual will react to a drug - paving the way for drugs with fewer side effects, or finding new therapeutic uses for existing medications.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Could be the beginnings of a win to the in silico approach to drug development: Cloud Pharmaceuticals is working with University of Florida to develop new cancer drugs that are conceived on a computer. The Research Triangle Park-based startup will share intellectual property with the university, and the two will jointly fund 10 research projects. So far, […]
We’re all plenty familiar with in-vivo and in-vitro, but Cloud Pharmaceuticals is taking the “in-silico“ approach to drug development. Its “inverse design” platform uses cloud supercomputing to cherry pick and formulate molecules that will work as new medications – cutting out much of the early lab expenses by conducting the earliest drug discovery processes virtually. The Research Triangle […]